RxDoctor Payments Data

Sachin Mehta, MD

Physical Medicine & Rehabilitation · Indianapolis, INNPI 1053571224

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 81.7% of it on its own, with 19 other manufacturers making up the rest. Among physical medicine & rehabilitation clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,187in general payments, 2019–2025

Across 253 payments — averaging $237.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$49K
  • GRT US Holding, Inc.$7K
  • Merz Pharmaceuticals, LLC$1K
  • Avanir Pharmaceuticals, Inc.$1K
  • Merz North America, Inc.$512
  • Medtronic$226
  • plus $719 from 14 others

What the payments were for

  • Consulting fees$13,65023%
  • Speaking & faculty fees$32,80054%
  • Travel & lodging$6,21810%
  • Food & beverage$6,39811%
  • Education$1,1212%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,187 in reported general payments places this provider in the 95th percentile of 140 physical medicine & rehabilitation providers in Indiana.

See all physical medicine & rehabilitation providers in Indiana

Medicare billing

Part B allowed, 2024
$715,211
Medicare patients
586
Services billed
84,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine16$25,144
Baclofen141$3,550
Gabapentin57$2,252
AmantadineAmantadine Hcl18$1,434
Meloxicam16$1,023
Midodrine Hcl13$514
Cefazolin Sodium14$338
Pregabalin12$257
Fludrocortisone Acetate15$256
Cyclobenzaprine Hcl12$254
Fluoxetine Hcl13$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$1,002$25,14416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 physical medicine & rehabilitation providers in Indiana.

Other physical medicine & rehabilitation in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →